Table 2.
Medication-related risk a | Examples b | |
High (risk score 4) | Anthracyclines; trastuzumab; cyclophosphamide; 5‑fluorouracil | |
Intermediate (risk score 2) | Pertuzumab; vinblastine; capecitabine; ponatinib | |
Low (risk score 1) | Bevacizumab; imatinib | |
Rare (risk score 0) | Carboplatin; fludarabine; paclitaxel; rituximab | |
Patient-related risk factors (1 point per item) | ||
– Cardiomyopathy or heart failure – Coronary artery disease or equivalent (including peripheral artery disease) – Hypertension – Diabetes mellitus – Prior or concurrent anthracyclines – Prior or concurrent chest irradiation – Age <15 years or >65 years – Female gender | ||
Overall risk by CRS and intensity of monitoring | ||
>6 5–6 3–4 1–2 0 |
Very high High Intermediate Low Very low |
aThe highest medication-related risk score (e. g. 4, 2, 1 or 0) is used for calculation of the CRS
bSee the supplementary table for each separate agent and/or regime. Adapted from: [14]